Rivia, a Swiss startup specialising in AI-driven analytics and clinical trial data infrastructure for biotechs, has secured €3 million in seed funding. The investment round was led by Speedinvest, which recently invested in Haaven and Alinia.
How will Rivia use the investment?
The funds will be used to hire new teams across engineering and client services. It will also be used to advance product development to fully harness the potential of integrated trial data and strengthen its position as the unified data platform for biopharma clinical trials.
“We at Speedinvest are beyond excited to work closely with Erik and Tiago and lead Rivia’s seed round. Rivia’s infrastructure and AI-powered platform fundamentally changes how biotech companies access and analyse their clinical trial data, glean insights, and make real-time decisions. The feedback from their customers is phenomenal and we believe Rivia has the potential to become the gold standard in the industry,” commented Andrea Zitna, Partner at Speedinvest.
“We strongly believe Rivia’s two-pronged value proposition, focused on enhancing operational efficiency and reducing risks, is exactly what thousands of biotechs globally have been waiting for — and we are excited to see this European company deliver on it with such deep domain expertise, creativity, and ingenuity,” said Marta G. Zanchi, Founder & Managing Partner at Nina Capital.
What challenge does it address?
As biotech innovation accelerates with developments like mRNA vaccines and gene-editing therapies, the need for agile, tech-centric clinical trial approaches has never been more critical. Rivia’s platform addresses this need, ensuring that groundbreaking treatments can navigate the complexities of clinical trials more efficiently.
It offers a solution that not only improves efficiency but also significantly increases the likelihood of new therapies reaching the market.
What does Rivia do?
Founded by seasoned biopharma experts familiar with the industry’s pain points – Erik Scalfaro and Tiago Kieliger in 2022, Rivia is an AI-driven analytics and clinical trial data infrastructure for Biotechs. The company offers an easy-to-use platform that simplifies clinical trial data acquisition and understanding through interactive analytics and AI-driven data insights. This transition accelerates and improves Biotech decision-making to drive higher therapeutic success.
Its technology empowers biotechs to analyse trial data more effectively, facilitating quicker and more efficient pathways to market for their therapies. The transition to innovative drug treatments, including mRNA vaccines, newly approved gene-editing therapies, and AI-discovered drugs, underscores the critical need to evolve from traditional, slow clinical trial practices to a nimble, tech-centric approach that navigates the uncertainties associated with these groundbreaking treatments.
Rivia’s impact is already noticeable with clients across Europe and the US, including Abcentra. Chris Farina, Abcentra’s Chief Executive Officer, shared: “Rivia is revolutionising how biotech companies make decisions using clinical trial data. By providing quick access and maintaining all trials as a dynamic, evolving dataset, Rivia saves time and enhances our understanding of patient responses. Integrating safety, efficacy, and dosing data is crucial for evaluating trial data in real-time, both during and after trials.”
What do we think about Rivia?
Reportedly, only 13% of therapies that enter clinical trials reach the market, showing a pressing need for solutions that accelerate and improve Biotech decision-making to drive higher therapeutic success. As Rivia has secured investment at this time, it is a testament to the company’s growth opportunity.
